Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.50 |
| ▸ | ESRRB | O95718 | 1/20 | 0.50 |
| ▸ | ESRRA | P11474 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29729491 | 1.00 | ESR1 (0.50) | ESR1ESR2ESRRBESRRATTR | |
| Bromide SCHEMBL9069911 | 0.98 | ESR1 (0.49) | ESR1ESR2ESRRBESRRATTR | |
| SCHEMBL1043161 | 0.84 | TLR8 (0.51) | ESR1ESR2ESRRBESRRATTR | |
| SCHEMBL29612575 | 0.84 | TLR8 (0.51) | ESR1ESR2ESRRBESRRATTR | |
| Ammonia Solution, Strong SCHEMBL27616951 | 0.82 | TLR8 (0.50) | ESR1ESR2ESRRBESRRATTR | |
| SCHEMBL1888577 | 0.79 | NR4A2 (0.66) | PARP1DYRK1BNR4A2HSD17B10MEN1 | |
| SCHEMBL30051309 | 0.79 | NR4A2 (0.66) | PARP1DYRK1BNR4A2HSD17B10MEN1 | |
| SCHEMBL30819181 | 0.79 | PARP1 (0.47) | PARP1MAPKAPK2NR4A2HSD17B10MEN1 | |
| SCHEMBL1332713 | 0.79 | PARP1 (0.47) | PARP1MAPKAPK2NR4A2HSD17B10MEN1 | |
| SCHEMBL29576809 | 0.78 | TLR8 (0.43) | DYRK1BNR4A2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | TERNS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250319214-A1 | A NOVEL KIT FOR RADIOPHARMACEUTICAL PREPARATION OF A RADIOMETAL LABELED CHELATE-FUNCTIONALIZED TARGETING CONJUGATE | Life Molecular Imaging Ltd. (GB) | 2025-10-16 | — | — | US | disclosed |
| EP-4622970-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-10-01 | — | — | EP | disclosed |
| WO-2024112854-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024112854-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2023275195-A2 | A NOVEL KIT FOR RADIOPHARMACEUTICAL PREPARATION OF A RADIOMETAL LABELED CHELATE-FUNCTIONALIZED TARGETING CONJUGATE | LIFE MOLECULAR IMAGING LIMITED (GB) | 2023-01-05 | — | — | WO | disclosed |
| US-20220281849-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. | 2022-09-08 | — | — | US | disclosed |
| EP-4017875-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-1181059-C | Quinoline-4-base deviative I | - | 2004-12-22 | — | — | CN | disclosed |
| EP-1088818-B1 | Quinolin-4-yl derivatives | HOFFMANN LA ROCHE (CH) | 2004-11-03 | — | — | EP | disclosed |
| US-6440995-B1 | NMDA-RECEPTOR SUBTYPE SELECTIVE BLOCKERS | HOFFMAN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| US-6339093-B1 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-01-15 | — | — | US | disclosed |
| EP-1090917-A1 | Quinolin-4-yl derivatives and their use as NMDA-receptor subtype blockers | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| CN-1290698-A | Quinoline-4-base deviative I | HOFFMANN LA ROCHE (CH) | 2001-04-11 | — | — | CN | disclosed |
| EP-1088818-A1 | Quinolin-4-yl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-04 | — | — | EP | disclosed |
| US-5506235-A | Quinoline derivatives as immunostimulants | PFIZER INC. (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0597003-A1 | QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS | PFIZER INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| WO-1993003030-A1 | QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS | PFIZER INC. (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | ESR1 1751/4885ESR2 248/4885ESRRB 149/4885 |
| US-20220281849-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | ESR1 508/4885ESR2 135/4885ESRRB 92/4885 |
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | RIPK1, RIPK2, RIPK4 | ESR1 4074/4885ESR2 1948/4885ESRRB 2035/4885 |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | RIPK2, RIPK1, RIPK4 | ESR1 4773/4885ESR2 4201/4885ESRRB 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.